Currently, after angioplasty is performed to unblock narrowed coronary arteries, a patient receives anticoagulant therapies such as heparin, aspirin, and plavix. However, in 30-40% of cases the narrowing recurs.
In its animal studies Thromgen has demonstrated that Thrombostatin delays blood clots formation in coronary and carotid arteries.
Dr Alvin Schmaier, the company’s CEO, explained the goals of the study. “First, we must demonstrate that the current form of Thrombostatin is safe for human use and how it is tolerated in people. When that’s established we can move on to studies comparing its performance to the most widely-used anticoagulant therapies. We believe Thrombostatin has the opportunity to be a first-in-class thrombin receptor activation antagonist.”